Switching to vadadustat for anemia in dialysis patients
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests a new pill, vadadustat, for people on dialysis who have anemia. It looks at whether switching from the current treatment (Epogen) to this pill is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You receive dialysis at a center at least 3 times a week.
- You are currently taking Epogen (a medicine to help your body make red blood cells).
- Your hemoglobin (a measure of red blood cells) is between 9 and 11.4 in recent tests.
- Your iron levels (measured by transferrin saturation and ferritin) are within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two anemia medicines for people with chronic kidney disease (CKD) who are not on dialysis. It aims to find a more convenient pill option (daprodustat) versus a commonly used injection (epoetin alfa).
This trial tests a new pill called vadadustat to see if it can improve anemia (low red blood cells), quality of life, and inflammation in people on peritoneal dialysis. It may offer a more convenient way to manage anemia compared to current injections.
This study tests an experimental medicine for anemia in people with kidney disease who are on dialysis. It aims to see if it can help raise blood counts safely compared to standard treatments.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
This study tests whether a pill called roxadustat can help improve kidney oxygen levels in people with diabetes-related kidney disease and anemia. It may help boost your red blood cells and improve how your kidneys work.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
Hear when a new Anemia Associated With Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.